|

Crizotinib Clinical Trials

10 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Alectinib, Brigatinib, Carboplatin, Lorlatinib, MET Tyrosine Kinase Inhibitor PF-02341066 +9 more

Pipeline

Phase 1: 1Phase 2: 7Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Hunan Province Tumor Hospital2
  • University Health Network, Toronto1
  • The Netherlands Cancer Institute1
  • Sun Yat-sen University1
  • Oslo University Hospital1

Indications

  • Cancer10
  • Lung Cancer5
  • Non Small Cell Lung Cancer3
  • MET Activating Mutation1
  • ROS1 Gene Rearrangement1

Other8 trials

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Phase 3
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Phase 2
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Phase 2
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Phase 2
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
Phase 2
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Los Angeles, California1 trial

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

UCLA Medical Center

Phase 1/2

Houston, Texas1 trial

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.